Not Cleared Post-NSE

DEN000007 - QUANTA LITE ASCA (S. CEREVISIAE) IGG ELISA

DEN000007 is an FDA 510(k) submission for QUANTA LITE ASCA (S. CEREVISIAE) IGG ..., manufactured by Inova Diagnostics, Inc.. The device is a Class 2 Immunology device with product code NBT cleared through the Post-NSE 510(k) pathway after a 29-day FDA review.

DEN000007 · Inova Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2000
Decision
29d
Days
Class 2
Risk

DEN000007 is an FDA 510(k) submission (not cleared) for the QUANTA LITE ASCA (S. CEREVISIAE) IGG ELISA. Classified as Antibodies, Saccharomyces Cerevisiae (s.cerevisiae) (product code NBT), Class II - Special Controls.

Submitted by Inova Diagnostics, Inc. (San Diego, US). The FDA issued a Not Cleared (DENG) decision on August 16, 2000 after a review of 29 days.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5785 - the FDA immunology device framework. The Traditional 510(k) pathway requires demonstration of substantial equivalence to a legally marketed predicate device - a standard the FDA determined was not met in this submission.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. This submission did not achieve clearance, indicating the FDA determined the device lacked sufficient predicate equivalence under the Immunology review framework.

FDA 510(k) Submission Details - DEN000007

510(k) Number DEN000007 FDA.gov
FDA Decision Not Cleared Not Substantially Equivalent (DENG)
Date Received July 18, 2000
Decision Date August 16, 2000
Days to Decision 29 days
Submission Type Post-NSE
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
76d faster than avg
Panel avg: 105d · This submission: 29d
Pathway characteristics

NBT Device Classification - Class 2, Special Controls

Product Code NBT Antibodies, Saccharomyces Cerevisiae (s.cerevisiae)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5785
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - NBT Antibodies, Saccharomyces Cerevisiae (s.cerevisiae)

All 7
Devices cleared under the same product code (NBT) and FDA review panel - the closest regulatory comparables to DEN000007.
IMMULISA ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY (ASCA) (IGG)
K032850 · Immco Diagnostics, Inc. · Mar 2004
IMMULISA ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY (ASCA) (IGA)
K032860 · Immco Diagnostics, Inc. · Mar 2004
QUANTA LITE ASCA (S. CEREVISIAE) IGA ELISA
K000733 · Inova Diagnostics, Inc. · May 2001
DEN000007 · QUANTA LITE ASCA (S. CEREVISIAE) IGG ELISA
Download PDF Inova Diagnostics, In…